Recent studies have shown that patients with glioma with the IDH mutation have improved prognoses compared with those without (3, 4), and stratification by IDH mutation status and its biochemical consequences may offer new opportunities for the diagnosis, monitoring, and treatment of patients with glioma (5, 6). Here, IDH2 is linked to central nervous system cancer.